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A wider application of siRNA- and miRNA- based ther-
apeutics is restricted by the currently available delivery
systems. We have designed a new type of small mole-
cule carrier (SMoC) system for siRNA modeled to inter-
act with cell surface proteoglycans. This bifurcated
SMoC has similar affinity for the model proteoglycan
heparin to an equivalent polyarginine peptide and
exhibits significant mRNA knockdown of protein levels
comparable to lipofectamine and the previously
reported linear SMoC.
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Small interfering RNAs (siRNA), which are capable of cata-
lytically silencing specific genes via the RNA interference
(RNAi) pathway, are attractive candidates for therapeutics
for a wide range of diseases including genetic disorders
and cancer. The direct application of unmodified siRNA to
the target tissue has shown to be successful in clinical tri-
als, for example an siRNA against a mutated form of kera-
tin 6a to treat the skin condition pachyonychia congenita
(TD101, Pachyonychia Congenita Project) (1), and several
siRNA-based treatments for age-related macular degener-
ation (2), in which the naked siRNA is injected directly into
the affected area. However, systemic delivery of siRNA,
which is required for targeting internal organs and tumors,
is more problematic as siRNA is readily degraded by endog-
enous nucleases and is rapidly cleared by the renal system.
In addition, its large size and high anionic surface charge
prohibits siRNA from crossing the plasma membrane and
reaching the RNAi machinery in the cytoplasm (3).
To be systemically effective, siRNA must be formulated in
such a way as to overcome these delivery barriers. siRNA
encapsulated in nanoparticles which protect the siRNA
from degradation and improve its half-life in vivo as well as
aiding cell targeting and internalization is a popular strat-
egy for increasing delivery efficiency (4). Several siRNA-
containing nanoparticles have progressed to clinical trials,
including TKM-PLK1 by Tekmira, currently in Phase II tri-
als, which uses nucleic acid-lipid particles (LNPs) (5,6) for
patients with advanced solid tumors. Alnylam in partner-
ship with Tekmira has developed two further LNP-based
therapeutics, which are also currently in clinical trials: ALN-
VSP in Phase II for liver cancer (7) and ALN-TTR01 for
transthyretin-mediated amyloidosis which has completed
Phase I trials (8). Another success for nanoparticles has
been Calando’s CALAA-01, in which siRNA complexed by
a cationic cyclodextrin polymer has demonstrated for the
first time in humans that systemically delivered siRNA can
specifically silence genes (9), and is now in Phase I clinical
trials. CALAA-01 consists of siRNA against the M2 subunit
of ribonucleotide reductase (RRM2), which is involved in
the proliferation of cancer cells, and targeted to cancer
cells via a human transferrin protein targeting ligand.
Patients with metastatic melanoma were exposed to the
drug via 30 min iv infusion and resulted in significant
reduction of RRM2 in the tumor cells. As in CALAA-01,
polyethylene glycol (PEG) is frequently used to coat nano-
particles to prevent aggregation and binding to serum pro-
teins as well as to evade detection by the immune system
(10,11). In addition, once the nanoparticles reach their tar-
get cells, they must penetrate the plasma membrane in
order to allow the siRNA to access the RNA-induced
silencing complex (RISC) located in the cytoplasm (12).
Cationic polymers such as polyethyleneimine (13), lipids
(5,6,14), and cell-penetrating peptides (CPPs), including
penetratin (15), polyarginine (16), and MPG (17) have
been used to deliver siRNA in vivo, and form complexes
via electrostatic interactions which neutralize the charge
of the oligonucleotide and allow interaction with cell
surface lipids and proteoglycans. As well as shielding the
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siRNA charge, these cationic materials have been found
to promote cell entry of siRNA as they are effective at
crossing cell membranes. Although the exact mechanism
of cellular entry adopted by these polymers and peptides
remains unclear, it is suggested that binding to cell sur-
face proteoglycans such as heparan sulfate and chon-
droitin sulfate via their glycosaminoglycan (GAG) chains
may be an initial internalization step, activating Rac1 and
triggering subsequent rearrangement of the F-actin cyto-
skeleton leading to macropinocytosis initiation (18). Sev-
eral studies have used heparin, a highly sulfated form of
heparan sulfate, to estimate binding affinities of CPPs to
cell surface GAGs, which were found to be in the micro-
molar to nanomolar range (19,20), while a more recent
study shows evidence that CPPs are able to form clus-
ters with multiple heparin chains (21).
We previously described that the small molecule carrier
(SMoC) class of compounds, which are small molecule
mimics of penetratin, show potential as siRNA delivery
agents (22), showing similar levels of gene silencing in
IMR-90 cells to the commonly used transfection reagent
Lipofectamine. SMoCs possess cationic guanidine
groups linked to a biphenyl backbone, forming amphi-
pathic alpha-helix mimics which are capable of crossing
cell membranes (23,24). We postulated that the positive
charges may be partially stabilized by p-cation interac-
tions with the biphenyl backbone to promote electrostatic
binding to siRNA and to anionic cell surface proteogly-
cans. The most successful SMoC compound for siRNA
transfection described thus far is 4G-SMoC-SSPy 1,
(Figure 1, see Figure S1 for the naming convention for
SMoCs). In the present study, we hypothesized that a
bifurcated SMoC compound, 4G-BfSMoC-COOH, 2
would achieve the twin aims of cell surface proteoglycan
binding and more flexible chemical synthesis. We
observed that 2 retains the ability to complex and deliver
siRNA, resulting in knockdown of the cell cycle gene
cdc7. 4G-BfSMoC-COOH, 2 and other SMoCs show sig-
nificant binding to heparin as a model for cell surface
proteoglycans. 2 is easily synthesized and includes a
central chemical ‘handle’ that will allow covalent attach-
ment to other biomolecules.
Methods and Materials
Starting materials were either commercially available or
synthesized according to methods reported in the litera-
ture. 1H and 13C NMR spectra were recorded on either a
Bruker AMX-300 or a Bruker AMX-500 spectrometer.
Chemical shifts are reported as ppm relative to TMS inter-
nal standard. Mass spectra were recorded on either a
Fisons VG70-SE spectrometer (EI, FAB) or an Agilent 6100
Series LC-mass spectrometer (Wokingham, Berkshire, UK)
using either a C-18 or C-4 column. Microwave reactions
were carried out using a CEM Discover microwave. All
compounds were purified to ≥ 95% as measured by
LC-MS. Proteoglycan binding was recorded using an Agi-
lent 1200 series HPLC system equipped with a diode
array detector and HiTrap heparin agarose column. A
complete list of 1H NMRs for compounds used in this
study is given in the supplementary information (Table S1).
Molecular modeling
Molecular modeling and dynamics were carried using
Molecular Operating Environment (MOE) package (version
2011.10). The framework structures 3 and 4 were initially
built in MOE (Chemical Computing Group, Montreal,
Canada) using the ‘Molecular Builder’ with an extended
conformation. All the guanidine groups are in +1 charge,
reflecting the protonated state of the groups. Then, the ini-
tial structures were subjected to energy minimization using
MMDD94X force field. The energy minimized structures of
3 and 4 were then carried through for dynamics simula-
tions. All molecular dynamics simulations were conducted
in a cube of water of depth of 10 A using ‘Simulations-
Dynamics’ in MOE. The protocol used in dynamics simula-
tions is as follows: algorithm – Nose-Poincare-Andersen
Hamiltonian equations of motion (NPA); temperature –
constant at 300°K; mode – equilibration for 100 ps, force-
field – MMFF94X, cutoff at 8 A. Conformations were
collected in trajectory files every 0.5 ps, providing 200
conformers for each run for each molecule. The molecular
Figure 1: Chemical structures of 4G-SMoC-SSPy, 1 and 4G-
BfSMoC-COOH, 2.
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dynamics simulations were also run in YASARA software
(25) with similar results.
Data analysis, such as distance measurement, was carried
out also in MOE using the graphics interface. The pairwise
distances between the carbon atoms of the guanidine group
from different phenyl rings in each molecule 3 or 4 were
measured for each conformation. A histogram summarizing
the data was calculated and plotted using Microsoft Excel.
Crystal structure information for heparin (PDB ID: 1HPN)
and chondroitin sulfate (PDB ID: 1C4S) was obtained from
the PDB and imported into DS Visualizer (Accelrys, San
Diego, CA, USA) and the distance between sulfate
residues measured between sulfur atoms.
Synthesis
3,5-bis(2,3-bis(2-(((benzyloxy)carbonyl)amino)
ethoxy)phenyl)benzoic acid 6
To a degassed solution of potassium (2,3-bis(2-(((benzyloxy)
carbonyl)amino)-ethoxy)phenyl)trifluoroborate (22) (3.62
g, 6.34 mmol) in isopropanol/water (2/1, 21 mL) was added
PdCl2dppf.CH2Cl2 (123 mg, 0.15 mmol) and triethylamine
(1.77 mL, 12.68 mmol) and the solution stirred for 2 min.
3,5-Diiodobenzoic acid, 5 (789.1 mg, 2.11 mmol) was
added ,and the reaction heated in a microwave reactor for
10 min at 75 °C. The reaction mixture was cooled, filtered,
and 1 M HCl added (50 mL). The product was extracted
with dichloromethane (3 9 25 mL), and the combined
organic extracts were washed with brine (50 mL), dried over
MgSO4, filtered, and concentrated under vacuum. The mix-
ture was purified by flash column chromatography using a
gradient of 0–50% ethyl acetate in cyclohexane and the title
product (1.7 g, 80% yield) obtained as a colorless oil.
1H-NMR (500 MHz, CDCl3) d: 3.27 (s, 4H, 2 9 CH2),
3.48–3.74 (m, 8H, 4 9 CH2), 4.11 (s, 4H, 2 9 CH2),
4.97–5.10 (m, 8H, 4 9 Ph-CH2OCONH), 6.68–7.11 (m,
6H, 6 9 ArH), 7.23–7.32 (m, 20H, 20 9 Cbz-ArH), 7.66–
8.29 (m, 3H, 3 9 ArH).
13C-NMR (500 MHz, CDCl3) d: 40.81 (CH2), 41.13 (CH2),
66.87 (Cbz CH2), 68.22 (CH2), 113.43, 123.04, 124.90,
128.20 (Cbz ArC), 128.51 (Cbz ArC), 135.03, 136.44,
138.37, 145.06, 152.02, 156.77 (C = O).
HRMS-ES (m/z): [M  H] calcd for C59H57N4O14,
1045.3871; found, 1045.3804.
3,5-bis(2,3-bis(2-(((tert-butoxycarbonyl)guanidino)
ethoxy)phenyl)-benzoic acid
To a solution of 3,5-bis(2,3-bis(2-(((benzyloxy)carbonyl)
amino)ethoxy)phenyl)-benzoic acid 1 (813 mg, 0.7 mmol)
in dichloromethane (20 mL) was added 30% hydrogen
bromide in acetic acid (5 mL) dropwise and the mixture
stirred at room temperature for 3 h. The reaction was
diluted with dichloromethane (20 mL) and the product
extracted with water (3 9 20 mL). The aqueous extracts
were carefully dried under vacuum for several hours. The
crude amine was then dissolved in methanol (20 mL), and N,
N0-Di-Boc-1H-pyrazole-1-carboxamidine (922 mg, 3.15 mmol)
and DIEA (1.22 mL, 7 mmol) were added. The reaction
was stirred at room temperature for 24 h under nitrogen.
The solvent was removed under reduced pressure and the
residue redissolved in ethyl acetate (50 mL) and 1 M HCl
added (50 mL). The layers were separated, and the aque-
ous layer washed with ethyl acetate (3 9 20 mL). The
combined organic extracts were washed with brine
(50 mL), dried over MgSO4, filtered, and concentrated
under vacuum. The product was purified by flash column
chromatography using a 0–25% ethyl acetate gradient in
cyclohexane. The product was obtained as an off-white
solid (651 mg, 63% yield).
1H-NMR (500 MHz, CDCl3) d: 1.42–1.51 (m, 72H,
24 9 Boc-CH3), 3.55 (m, 4H, 2 9 CH2), 3.87 (m, 4H,
2 9 CH2), 3.93 (m, 4H, 2 9 CH2), 4.23 (m, 4H, 2 9 CH2),
6.99 (m, 2H, 2 9 ArH), 7.03 (m, 2H, 2 9 ArH), 7.13 (m, 2H,
2 9 ArH), 7.98 (m, 1H, ArH), 8.28 (m, 2H, 2 9 ArH), 8.66 (m,
2H, 2 9 NH), 8.81 (m, 2H, 2 9 NH), 11.45 (bs, 1H, COOH).
13C-NMR (500 MHz, CDCl3) d: 28.06 (Boc-CH3), 28.17
(Boc-CH3), 28.36 (Boc-CH3), 28.39 (Boc-CH3), 53.49
(CH2), 67.43 (CH2), 79.06 (Boc CCH3), 79.35 (Boc CCH3),
82.80 (Boc CCH3), 83.20 (Boc CCH3), 113.31, 123.34,
124.77, 129.78, 135.12, 138.33, 145.16, 152.11, 153.01,
156.43, 163.54, 169.33 (COOH).
HRMS-ES (m/z): [M+ H]+ calcd for C71H107N12O22,
1479.7423; found, 1479.7423.
4G-BfSMoC-COOH, 3,5-bis(2,3-bis(2-
(guanidinoethoxy))phenyl)-benzoic acid 2
The tetra-Boc compound (30 mg, 0.02 mmol) was dis-
solved in DCM (2 mL), and TFA/m-cresol (95/5, 2 mL)
was added and the mixture stirred for 4 h at room temper-
ature. The solvent was removed under vacuum, and the
residue washed three times with ether. The product was
dissolved in water and lyophilized to form the tetra-TFA
salt as a white solid (23 mg, 0.02 mmol, 100% yield).
1H NMR (600 MHz, D2O) d 8.17 (d, J = 1.6 Hz, 2H), 7.86
(d, J = 1.1 Hz, 1H), 7.33–7.27 (m, 2H), 7.20 (dd, J = 8.3,
1.2 Hz, 2H), 7.10 (dt, J = 15.6, 7.8 Hz, 2H), 4.35–4.29
(m, 2H), 4.02–3.97 (m, 2H), 3.73 (t, J = 4.9 Hz, 2H), 3.23–
3.18 (m, 2H).
13C NMR (151 MHz, D2O) d 171.06, 157.88, 157.21,
151.90, 144.44, 138.55, 135.89, 135.33, 130.64, 130.37,
126.24, 123.69, 114.53, 71.96, 67.55, 42.15, 41.61. Also
visible peaks for trifluoroacetate, 163.98, 163.74, 163.51,
163.27, 119.86, 117.93, 116.00, 114.06.
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HRMS-ES (m/z): [M+H]+ calcd for C31H43N12O6, 679.
3429; found, 679.3428.
2, 3, 20, 30-tetra(2-guanidino-ethyloxy)-4-cyanobiphenyl, 8,
(4G-SMoC-CN).
To a solution of 2, 3, 20, 30-tetra(2-[N, N’-bis(tert-
butoxycarbonyl)guanidino]-ethyloxy)-4-cyanobiphenyl 7 (22)
(40 mg, 0.0289 mmol) in DCM (2 mL) was added a solution
of TFA/m-cresol (95:5) (2 mL). The reaction mixture was
stirred at room temperature for 3 h. Solvent was evapo-
rated and the product precipitated from Et2O, washed three
times with Et2O, dissolved in water, and lyophilized to give
the title product (21 mg, 70%) as a white powder.
1H NMR (500 MHz, MeOH) d 7.50 (d, J = 8.0, 1H, aro-
matic), 7.20 (d, J = 8.0, 2H, aromatic), 7.15 (dd, J = 8.3,
1.6, 1H, aromatic), 6.91 (dd, J = 7.5, 1.6, 1H, aromatic),
4.38 (t, J = 5.0, 2H CH2), 4.24 (t, J = 5.2, 2H, CH2), 4.00
(t, J = 4.9, 2H, CH2), 3.92 (t, J = 4.9, 2H, CH2), 3.68 (dt,
J = 9.8, 5.1, 4H, 2 9 CH2), 3.28 (dd, J = 9.6, 4.7, 4H,
2 9 CH2).
HRMS m/z (ES+) 584.3186, calculated C25H38N13O4
+
584.3170.
Gel shift assay
GAPDH siRNA (Thermo Scientific, Loughborough, UK;
sequences used were sense 50 UGG UUU ACA UGU UCC
AAU AUU 30, antisense 50 Phosphate U AUU GGA ACA
UGU AAA ACC UU 30) was mixed in RNAse-free water with
varying concentrations of either SMoC, PySSCH2CH2CO-
RRRR-NH2, 9 (R4SSPy) or PySSCH2CH2CO-RRRRRRRR-
NH2, 10, (R8SSPy), (Peptide Synthetics, Ltd, UK) in the
molar ratios of 1/1, 1/5, 1/10, 1/20 and 1/50. The final siR-
NA concentration was 17 lM in 100 lL of water (1.7 nmol)
in each case. The complexes were incubated for 30 min at
room temperature. The samples were diluted with 29 RNA
loading dye (Fermentas, now Thermo Scientific) containing
ethidium bromide (composition 95% formamide, 0.025%
SDS, 0.025% bromophenol blue, 0.025% xylene cyanol FF,
0.025% ethidium bromide, 0.5 mM EDTA) and analyzed by
gel electrophoresis on a 1% agarose gel prepared using
109 MOPS buffer [0.4 M MOPS (pH 7), 0.1 M sodium ace-
tate, 0.01 M EDTA (pH 8)], loading 25 lL of sample into
each well. The gel was run at 5V/cm till the blue dye had
migrated 2/3 of the gel. The gels were analyzed by UV illumi-
nation and the ethidium bromide bands quantified using the
ImageJ software (NIH, Bethesda, MD, USA). The EtBr inten-
sities were plotted, a dose–response curve fitted and EC50
values calculated using the Origin software (OriginLab,
Northampton, MD, USA).
Cell culture
IMR-90 (ATCC# CCL-186) cells were obtained from LGC
Standards, UK, at population doubling (PD) 12. Cells were
cultured in Dulbecco’s modified Eagles Medium (DMEM)
(Invitrogen, Life Technologies, Paisley, UK) supplemented
with 10% Fetal Bovine Serum (Invitrogen) and 2 mM L-glu-
tamine (Invitrogen) at 37 °C and 5% CO2. 4T1 cells were
purchased from Caliper Life Sciences (Hopkinton, MA,
USA). MCF-7 cells were obtained from the European Col-
lection of Animal Cell Cultures, Porton Down, UK.
Confocal microscopy in vitro
Cell preparation: 1 9 104 4T1 (murine) and MCF-7 (human)
breast cancer cells were seeded in 35 mm diameter glass-
bottomed fluorodishes (WPI, Hitchin, Hertfordshire, UK).
These were incubated overnight to encourage adherence
and optimal subconfluent cell spreading for imaging. 4T1
cells were incubated with fresh RPMI-1640 Medium with
L-glutamine and sodium bicarbonate (Sigma-Aldrich, Poole,
Dorset, UK) supplemented with 10% (v/v) fetal calf serum
(FCS) (Gibco, Life Technologies, Paisley, UK, Invitrogen);
MCF-7 cells were incubated with fresh DMEM containing
0.365 g/L L-glutamine, 4.5 g/L glucose (BioWhittaker, Ver-
viers, Belgium), supplemented with 10% (v/v) FCS (Sigma-
Aldrich), 100 U/mL penicillin and 100 lg/mL streptomycin
at 37 °C in a humidified 5% CO2 incubator.
Confocal: Cells were observed using an inverted Olympus
Fluoview 1000 confocal laser-scanning microscope to
determine intracellular localization of the oligonucleotide.
Fluorescence confocal images were obtained using a 609
NA:1.35 oil immersion objective lens (Olympus Fluoview
FV1000; Olympus, Southend-on-Sea, UK). Original image
files were analyzed using Image J software. Analysis of the
labeled siRNA  4G-BfSMoC-COOH, 2 was performed
using image J to quantify the mean intracellular signal
intensity compared to the background level of fluores-
cence. A one-way ANOVA with Tukey’s multiple comparison
test was used to assess statistical significance. Appropri-
ate controls were used throughot.
RNA oligonucleotide, lipofectamine, and 4G-
BfSMoC-COOH, 2 preparation
The intracellular localization of Alexa Fluor Red Fluorescent
oligonucleotide (Invitrogen) supplied as a 20 lM stock of
Alexa Fluor 555-labeled, double-stranded RNA oligomer in
100 mM KOAc, 30 mM HEPES-KOH, pH 7.4, and 2 mM
MgOAc (annealing buffer) was determined through confocal
fluorescence microscopy. Lipofectamine RNAiMAX (Invi-
trogen). The oligonucleotide was diluted to a final concen-
tration of 1 lM either alone or in combination with 10 lM
4G-BfSMoC-COOH, 2. The initial dilutions were in phos-
phate buffered saline (PBS) (Lonza, Slough, UK). The oligo-
nucleotide/4G-BfSMoC-COOH, 2 mixture was allowed to
complex for 15 min at room temperature. Final dilutions
were made in the appropriate cell medium. Either cell line
was subsequently incubated with media (alone), oligonu-
cleotide(alone), 4G-BfSMoC-COOH, 2 (alone), or oligonu-
cleotide/4G-BfSMoC-COOH, 2 for 24 h. Lipofectamine
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controls were transfected according to manufacturer’s
instructions to a final concentration of 3.75 lL/mL + oligo-
nucleotide. Cells were washed twice with PBS and treated
with phenol-red-free media prior to confocal imaging.
siRNA transfection
Solutions were made up in Opti-MEM (Invitrogen);
100 nM cdc7 siRNA (sense 50-GCU CAG CAG GAA AGG
UGU UUU-30, antisense 50-AAC ACC UUU CCU GCU
GAG CUU-30; Applied Biosystems, Warrington, UK),
100 nM Accell Non-targeting siRNA 1 negative control siR-
NA (Thermo Scientific), 8 lL/mL Lipofectamine LTX
reagent (Invitrogen), 0.5 mM SMoC. SMoC/siRNA, and
Lipofectamine/siRNA complexes were made by mixing
equal volumes of the required solutions and incubating for
30 min at room temperature.
Cells were plated in 6-well plates at a density of 5 9 105
cells/well in 1 mL DMEM containing 10% FCS and 2 mM
glutamine and incubated at 37 °C under 5% CO2 for 24 h.
The media was removed and replaced with 1.6 mL Opti-
MEM (Invitrogen). Four hundred microliters of SMoC/
siRNA or Lipofectamine/siRNA complexes was added and
the cells incubated for a further 72 h. The final concentration
of SMoC was 50 lM and based on the dose–response
analysis reported previously (22).The cells were washed with
PBS and trypsinized and the pellet stored at 80 °C.
RNA purification and qRT-PCR
RNA was extracted from the cell pellets using the PureLink
RNA Mini kit (Invitrogen) using the protocol provided by the
manufacturer. RNA was quantified using a Nanodrop spec-
trophotometer, and 40 ng of RNA was mixed with Super-
script III RT/Platinum Taq Mix and SYBR Green Reaction
Mix from the Supersript III Platinum SYBR Green One-Step
qRT-PCR kit (Invitrogen) according with the manufacturer’s
protocol. PCR conditions were 50 °C for 3 min, 95 °C for
10 min (one cycle), 95 °C for 15 seconds, 47 °C for
30 seconds, 60 °C for 30 seconds (45 cycles), 95 °C
for 15 seconds, 60 °C for 15 seconds, ramp to 95 °C over
20 min (one cycle). Relative quantification data were
obtained using the comparative Ct method with Realplex
software according to the manufacturer’s protocol (Eppen-
dorf, Hamburg, Germany). cdc7 RNA was measured using
the following primers: forward primer: 50-AAC TTG CAG
GTG TTA AAA AAG-30: reverse primer: 50-TGA AAG TGC
CTT CTC CAA T-30. The following primers were used to
measure GAPDH: forward primer: 50-TCA ACT ACA TGG
TTT ACA TGT TC-30: reverse primer: 50-GAT CTC GCT CCT
GGA AGA T-30. The signal obtained from the cdc7 primers
was normalized using the signal from the GAPDH primers.
Proteoglycan binding
The test SMoCs and the marker oligoarginine peptides
R4SSPy, 9 and R8SSPy, 10 were applied to a heparin
agarose column (HiTrap, GE-Healthcare Life Sciences, UK)
(1 mL) and eluted with a gradient of sodium chloride from
500 to 1000 mM. The absorbance at 214 nM (CONH) was
recorded and exported to Origin 9.0. The signals were
normalized and replotted as shown in the Figure. HIVtat,
11, (sequence YGRKKRRQRRR) was obtained from
Sigma.
Statistical analysis
Groups were compared using an unpaired two-sample
Student’s t-test. A value of P < 0.05 was considered
significant.
Results
Design of a bifurcated SMoC derivative
As binding to cell surface GAGs such as heparan sulfate
and chondroitin sulfate is thought to play a role in CPP
internalization, the active transfection compound 1
(Table 1) was studied via molecular modeling and dynam-
ics for its ability to bind these proteoglycans. The struc-
tures of chondroitin sulfate and heparin, a highly sulfated
form of heparan sulfate, were obtained from the Protein
Databank, and the distances between sulfate residues
were measured (Figure 2A,B). Examination of the crystal
structure of heparin (pdb: 1HPN) revealed that the sulfate
residues were positioned in ‘clusters’ of three on alternat-
ing sides of the sugar chain. The distance between resi-
dues within each cluster varies between 6.1 and 7.8 A
with an average distance of 6.6 A, whereas the distance
between clusters on the same side of the chain averages
of 17.5 A (Figure 2A). Due to flexibility of the chain, it is
possible that in nature, the distances between sulfate resi-
dues may vary considerably from the crystal structure. For
the crystal structure obtained for chondroitin sulfate (pdb:
1C4S), the distance between sulfate groups was mea-
sured as 12.7 A (Figure 2B), with sulfate groups positioned
on alternating sides of the sugar chain. As the SMoC gua-
nidine groups may not be able to access sugars on oppo-
site sides of the chain, the distance between sulfates on
the same side was also measured and found to be
approximately 20.7 A.
To gauge the interaction between our molecules and hep-
arin and chondroitin sulfate, the pairwise distances
between the carbon atoms of the guanidine group from
different phenyl rings for each conformation observed dur-
ing molecular dynamics simulation of structure 3 were
measured; that is, four distances were measured: between
C2-C20, C2-C30, C3-C20, and C3-C30 as labeled in
Figure 3. The results are plotted as a histogram showing
the frequency of the C-C distances. More than 75% of the
time, the C-C distances are above 11 A. The most fre-
quently occurring distances between two carbons (35%)
are between 11 and 12 A, mainly between groups C3-C20
and C2-C30. The longest distance is averaged around
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Table 1: Proteoglycan binding: retention times of arginine rich peptides and SMoCs on a heparin column
Compound Structure Short name Guanidines
Retention
time
Reference for
compound
9 PySSCH2CH2CO-RRRR-NH2 R4SSPy 4 4.4 (22)
10 PySSCH2CH2CO-RRRRRRRR-NH2 R8SSPy 8 19.17 (22)
11 YGRKKRRQRRR HIV-1 tat 6 15.2 This study
1 See Figure 1 4G-SMoC-SSPy 4 8 (23)
2 See Figure 1 4G-BfSMoC-COOH 4 4.69 This study
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Figure 2: Modeling a new SMoC analogue for binding to cell surface glycosaminoglycans. (A) Examination of the crystal structure of
heparin. Clusters of three sulfate residues are observed, occurring on alternating sides of the sugar chain. Representative distances
between residues in the same cluster, and between residues of adjacent clusters on the same side of the chain are shown in A. (B)
Chondroitin sulfate crystal structure obtained from the PDB. The distances between sulfate ions are marked in A. (C) A representative
snapshot taken from the molecular dynamics simulation of 3. The average distance between the furthest guanidine groups is indicated in A.
(D) A snapshot from the molecular dynamics simulation of 4. The average distance between the furthest guanidine groups is indicated in A.
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16.48 A, contributed mainly from groups C3-C30. This dis-
tance is sufficient for binding to heparin sulfates in the
same cluster, as well as binding to chondroitin sulfates on
opposite sides of the sugar chain. However, to optimize
binding to these GAGs, the distance between guanidine
residues should be slightly increased in order that it is pos-
sible to bridge the gap between heparin sulfate clusters,
as heparan sulfate is less sulfated than heparin, and the
sulfate groups may be more sparsely arranged. Further-
more, macropinocytosis is initiated by clustering of GAG
chains attached to different proteoglycan molecules (26).
Therefore, increased spacing between SMoC guanidine
groups may allow for binding of sulfates on different GAG
chains.
To extend the distance between guanidine groups in the
SMoC structure, we decided to investigate the incorpora-
tion of an additional phenyl ring to the original structure, to
produce a bifurcated structure, 4 (Figure 3). Again molecu-
lar dynamics was carried out for this molecule. We pre-
dicted that the ring should be added at the same location
as the biphenyl bond to preserve the p-cation stabilization
of the guanidine charges (22). The pairwise distances
between the carbon atoms of the guanidine group from
different phenyl rings for each conformation observed dur-
ing molecular dynamics simulation of structure 4 were
measured; that is, four distances were measured: between
C20-C2″, C20-C3″, C30-C2″, and C30-C3″. From Figure 3,
almost half of the time (50%), the distances between any
2 guanidine carbon atoms are larger than 15 A; and 25%
of the distances are above 17 A, contributed mainly from
groups C30-C3″. Therefore, compound 2 is sufficient for
binding to adjacent sulfate clusters in heparin and may
also bind heparan sulfate in a different way to 1 at the cell
surface. The additional distance between guanidines may
also allow binding of additional sulfate groups on chon-
droitin sulfate, as well as increasing the possibility of
promoting clustering of GAG chains.
Synthesis of 4G-BfSMoC-COOH
The synthesis of the new SMoC partly followed the syn-
thetic route previously described for the biphenyl
4G-SMoC-SSPy, 1 (22) (Figure 4A). The additional phenyl
ring was added via 3,5-diiodobenzoic acid, 5 a commer-
cially available compound that also contains an acid for
use as a linker group to attach targeting ligands. The syn-
thesis made use of the trifluoroborate salt described previ-
ously (22), which had been synthesized in bulk, in order to
introduce the amine functionality for adding guanidine
groups. The terphenyl structure was created using a
Suzuki-Miyaura palladium coupling reaction under micro-
wave irradiation at 80 °C with the trifluoroborate salt, pro-
ducing the coupled product 6 in 80% yield. The
guanidinylation step proceeded in the presence of the
unprotected acid group using the pyrazole guanidinylation
reagent in 63% yield, demonstrating that the acid does
not react with the guanidinylation reagent. The guanidines
were deprotected with TFA to yield the final product 2.
The 4-cyano intermediate 7 described previously (22) was
utilized for the synthesis of the marker molecule 8 by de-
protection with trifluoroacetic acid/TIPS (Figure 4B).
Figure 3: Frequency of distances:
between the two carbon atoms of
the guanidine groups attached to
different phenyl rings for structures
3 and 4. The carbon atoms are
labeled in red in the diagram.
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siRNA complexation
To confirm that the new SMoC retains the ability to bind
siRNA, the binding affinity was assessed using a gel shift
assay and compared to our previously tested 4G-SMoC-
SSPy, 1 (Figure 5A). The intensity of the siRNA bands
detected using ethidium bromide is reduced in a dose-
dependent fashion with the addition of the SMoCs due
to neutralization of the negative charge, resulting in
immobilization of the siRNA on the gel. The EC50 calcu-
lated for 2 was 0.07 mM (Figure 5B), which is equivalent
to 1. This shows that 2 maintains the same level of siR-
NA-binding capabilities as its predecessor, the mainte-
nance of this interaction is not obvious as the distances
and angles between the phenyl groups displaying the
guanidines is altered; in addition, the less electron-rich
central phenyl ring might alter the strength of p-cation
interactions.
siRNA transfection observed using fluorescent
siRNA oligomers
To examine the intracellular localization of the 2-enhanced
siRNA import, we utilized confocal microscopy with fluor-
escently labeled siRNA (Figure 6). Quantitative analysis of
the relative uptake demonstrates that addition of (10 lM)
4G-BfSMoC-COOH, 2 resulted in 4.9-fold (P < 0.01)
increased uptake of the oligonucleotide-fluorophore in the
4T1 cells; and a 2.6-fold (P < 0.01) increase in the MCF7
cell line compared to siRNA alone. There was undetect-
able ‘background’ uptake of fluorescently labeled siRNA
alone in the 4T1 cell line (Figure 6A) and non-significant
uptake in the MCF-7 cells (Figure 6C). This indicates that
there is minimal uptake and retention of uncomplexed
oligonucleotide-fluorophore by MCF-7 cells at 24 h. The
difference between the two cell lines indicates that this
likely to be a cell specific process. Negative controls (with-
out oligonucleotide-fluorophore) showed no fluorescent
signal; thus, this background effect is unlikely to be artifact
but rather a feature of the uptake kinetics of the specific
A
B
Figure 4: Synthesis of 4G-
BfSMoC-COOH (A) and the marker
compound 4G-SMoC-CN (B).
Reagents: (a) PdCl2dppf. CH2Cl2,
Et3N, iPrOH/H2O, MW 80 °C
(80%), 10 min; (b) 30% HBr in
acetic acid, DCM, rt; (c) N,N0-Di-
Boc-1H-pyrazole-1-carboxamidine,
DIEA, DCM, room temperature,
17 h (63% over 2 steps); (d) TFA/
TIPS/H2O, rt, 4 h (100%).
A
B
Figure 5: 4G-BfSMoC-COOH, 2 and 4G-SMoC-SSPy, 1 have
similar affinity for siRNA. (A) GAPDH siRNA (17 lM) was mixed
with 1 or 2 at the molar ratios shown with a loading dye
containing ethidium bromide and run on a 1% agarose gel using
a 0.4 M MOPS buffer (pH 7.0) containing 0.1 M sodium acetate
and 0.01 M EDTA. The gel was visualized under UV illumination.
(B) The ethidium bromide intensities as a function of SMoC
concentration were fitted in Origin. The EC50 value and Hill
coefficient (P) were calculated from the binding curve.
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cell lines. Positive controls using lipofectamine demon-
strated 14.4-fold (P < 0.01) and 3.3-fold (P < 0.01)
increased uptake compared to siRNA alone in 4T1 and
MCF-7 cell lines, respectively. In both cases, there was
significant nuclear uptake at 24 h (Figure 6E,F). Other
compounds listed in Table 1 either were inactive as
reported previously (22) or in the case of the 4G-SMoC-
CN, 8 were utilized only as a control.
siRNA transfection using 4G-BfSMoC-COOH, 2
Both the original 4G-SMoC-SSPy, 1 and the new 4G-BfS-
MoC-COOH, 2 were used to transfect either cdc7 siRNA
or a negative control siRNA into IMR-90 primary human
fibroblasts at a final SMoC concentration of 50 lM as
described previously (22). The commonly used transfection
reagent Lipofectamine was also used as a positive
control, and the mRNA knockdown was determined by
quantitative real-time PCR (Figure 7). The new 4G-BfS-
MoC-COOH achieved a knockdown of cdc7 mRNA of
71% compared to the negative control siRNA, whereas
the original 4G-SMoC-SSPy produced a 45% knockdown
and was identical to Lipofectamine, as predicted by our
earlier study. However, the difference between the bifur-
cated SMoC and the original compound was not statisti-
cally significant in this study.
Proteoglycan binding of SMoCs compared to
polyarginine peptides and HIV-1 tat47–57
To determine the relative proteoglycan binding of SMoCs,
we utilized heparin bound to agarose beads and moni-
tored the retention time when a gradient of sodium
chloride (500–1000 mM) was applied to the column.
Polyarginine peptides R4SSPy, 9 and R8SSPy, 10 were
applied as markers. Selected overlaid traces are shown in
Figure 8 and the full dataset in Table 1. The affinities of
2G-SMoC, 12 a 4G-SMoC marker compound bearing a
1-CN group, 8, and 6G-SMoC, 14 (22) increase in propor-
tion to the number of guanidine groups. 4G-BfSMoC-
COOH, 2 shows similar affinity to the linear 3G-SMoC-
SSPy, 13 and somewhat less than the 4G-SMoCSSPy, 1
perhaps due to the carboxylic acid group which is nega-
tively charged at physiological pH. Affinity to heparin was
insensitive to the inclusion of the disulfide pyridyl group
(see entries for 4G-SMoC-CN, 8 and 4G-SMoC-SSPy, 1.
HIV-1 tat47–57, 11 showed less affinity than the R8SSPy
polyarginine peptide, 10 and similar affinity to 6G-SMoC
14. Attempts to determine the proteoglycan binding of
lipofectamine were unsuccessful using this technique. Pro-
teoglycan binding cannot be assessed as Lipofectamine is
a cationic liposome-based reagent, comprising a 3:1
(w ⁄ w) liposome formulation of the polycationic lipid 2,3-
dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-
A B
C D
E F
Figure 6: Cellular uptake of fluorescent siRNA. Confocal microscopy of cells treated with AlexaFluor Red Fluorescent Oligonucleotide
 4G-BfSMoC-COOH, 2. Cells were treated with oligonucleotide-fluorophore alone (A) 4T1 and (B) MCF7; or treated with oligonucleotide-
fluorophore plus 4G-Bf-SMoC-COOH (C) 4T1 and (D) MCF-7 or oligonucleotide plus lipofectamine (E) 4T1 and (F) MCF-7 (scale = 20 lm).
Quantitative analysis of the relative cellular uptake demonstrates that addition of the 4G-BfSMoC-COOH, 2 resulted in 4.9-fold (P < 0.01)
increased uptake of the oligonucleotide-fluorophore (siRNA) in the 4T1 cells; and a 2.6-fold (P < 0.01) increase in the MCF7 cell line.
There was evidence of nuclear uptake in the 4T1 cell line (Figure 6C, white arrow). In cells treated with Lipofectamine plus siRNA, we
observed 14.4-fold and 3.3-fold increase uptake in 4T1 and MCF-7 cell lines, respectively. There was significant nuclear uptake in both
cell lines following treatment with Lipofectamine (Figure 6D and E, white arrows). The differing level of background uptake (siRNA alone) is
likely due to the differing characteristics of the two cell lines including doubling times and uptake kinetics.
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1-propanaminium trifluoroacetate (DOSPA) and the neutral
lipid dioleoyl phosphatidylethanolamine (DOPE) in mem-
brane-filtered water. The only UV active component is
expected to be DOSPA with a single weak amide UV
absorbance expected at 214 nm. However, using our
standard conditions and monitoring at 214 nm, we
observed only a peak at the solvent front even with 10 lg
of Lipofectamine injected (data not shown).
Discussion
The development of a delivery vector that is able to com-
plex and protect siRNA in vivo as well as achieve efficient
and targeted cellular internalization would be a major
advancement for the therapeutic use of siRNA. Multicom-
ponent siRNA delivery nanoparticles may consist of layers
of different materials, such as cationic polymers for siRNA
complexation, PEG to increase serum stability, and target-
ing ligands to confer cell specificity. An efficient siRNA
transfection vector should tightly package the siRNA, bind
to the cell surface so as to induce macropinocytosis, and
finally escape from the endosome into the cytoplasm in
order for the siRNA to act on the RNAi machinery and
silence the target gene. In this study, we have examined
the ability of the SMoC class of transporter to achieve the
earlier stages of this process – namely siRNA complexa-
tion and cell surface proteoglycan binding.
We previously showed that the protein transduction com-
pound 4G-SMoC-SSPy, 1 was also active as a siRNA
delivery vehicle. It was demonstrated that SMoCs were
capable of packaging siRNA via electrostatic complexation
through the guanidine side chains, thus neutralizing the
siRNA negative charges. We also postulated that the
biphenyl ring system of 4G-SMoC-SSPy formed p-cation
interactions with the guanidine groups, therefore shielding
the positive charges during membrane penetration, as pre-
dicted for penetratin. In the present study, we develop the
structure of the original SMoC to produce a siRNA delivery
agent that is able to bind sulfate groups on adjacent cell
surface GAGs, is simpler to synthesize and contains a
chemical ‘handle’ for potential conjugation.
The new 4G-BfSMoC-COOH, 2 described has been
molecularly designed to explore binding to the common
GAGs heparan sulfate and chondroitin sulfate, which have
been shown to interact with cell-penetrating peptides as a
precursor to internalization. In a model system utilizing the
more highly sulfated proteoglycan heparin, we observed
that the SMoCs bound with similar affinity to the reference
tetra and octa-arginine 10, 11, and HIV-1 tat peptides.
4G-BfSMoC-COOH, 2 did not show increased binding
over linear SMoCs despite the clear indication from the
modeling studies that longer distances might be beneficial
for binding and the molecular dynamics studies indicated
that the larger structures were able to adopt more
extended conformations. We should be cautious, however,
in that cellular binding may differ from our model heparin
system. Several studies have suggested that the binding
of GAG by CPPs plays a role in cell penetration, with sub-
sequent receptor clustering leading to reorganization of
the actin cytoskeleton as a precursor to macropinocytosis
(18,20,27–30). Heparin has been used in binding assays
to determine GAG-binding affinities for several CPPs,
which are found to bind in the low micromolar to nanomo-
lar range (19), probably via bidentate hydrogen bonds
between arginine residues and sulfate groups. Recently a
report from the Dowdy laboratory challenged the impor-
tance of GAG binding for CPP internalization (31), and the
uptake of other peptides has been shown to be indepen-
dent of GAG binding (32,33). Further investigations will be
required to ascertain the exact influence of GAG binding
Figure 8: Relative binding to a heparin surface. The SMoCs
shown are applied to a HiTrap heparin column in PBS pH 7.4 and
eluted with an increasing gradient of NaCl 0.5–1 M. Polyarginine
peptides are added as references (half height peaks). A full list of
the retention times is shown in Table 1.
Figure 7: mRNA expression levels in cells treated with 4G-
BfSMoC-COOH:siRNA complexes. qRT-PCR data showing
cdc7mRNA expression in either untreated IMR-90 cells (blue) or
cells treated with Lipofectamine, 1, or 2 complexed to control
(red) or cdc7 (green) siRNA. Experiments were conducted in
triplicate. *, P < 0.05 compared to control siRNA.
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on the SMoC class of biomolecular transporter. The new
SMoC described here was easily synthesized, with the tri-
fluoroborate salt used in a Suzuki-Miyaura bicoupling step
to form the terphenyl structure. The success of this cou-
pling step demonstrates that the trifluoroborate salt may
be used to generate larger branched SMoC analogues
from simple starting materials. The bifurcated SMoC does
not show increased uptake compared to the original
4G-SMoC-SSPy, 1 reagent or to Lipofectamine; how-
ever, it does demonstrate that the disulfide pyridyl group,
and therefore potential reaction with cell surface thiols, is
not required for successful siRNA transfection. Further
optimization of this system is in progress.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Naming convention for SMoCs.
Table S1 Following a request from a reviewer we have
included all the 1H NMRs for the compounds used in this
study.
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